文献速递呼吸道感染

法国成人呼吸道合胞病毒感染住院及出院后中期并发症观察研究

In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study.
PubMed 文献 · Eur Respir J · 2022-03-03

该研究前瞻性纳入法国五家大学医院两个冬季因流感样疾病住院的成人,比较呼吸道合胞病毒(RSV)与流感患者的临床特征及结局。RSV占8%,流感占31%;RSV患者年龄更大、慢性呼吸或心脏病比例更高、住院时间更长,院内复合结局更差(aPR 1.5,95%CI 1.1-2.1),但出院后30/90天死亡及90天再入院复合结局无差异(aPR 1.1,95%CI 0.8-1.6)。

要点

  • 住院流感样疾病成人中RSV检出率8%,流感31%。
  • RSV患者年龄更大、慢性呼吸/心脏病更多、住院更长。
  • RSV院内复合结局比流感差,出院后中期结局相似。

核心结论

  • RSV感染导致严重呼吸道疾病,院内结局比流感更差,出院后中期结局与流感相似。

研究设计与样本

  • 前瞻性观察研究,纳入法国五家大学医院连续两个冬季(2017/2018和2018/2019)因流感样疾病住院的成人,共1428例。
  • 通过鼻咽拭子多重逆转录PCR检测RSV和流感病毒,RSV阳性者与RSV阴性及流感阳性住院患者比较。
  • 采用泊松回归模型估计RSV与流感感染院内及出院后结局的调整患病率比(aPR)。

主要发现

  • RSV检出率为8%(114/1428),流感病毒为31%(437/1428)。
  • RSV患者比流感患者年龄更大(平均73.0岁 vs 68.8岁,p=0.015)。
  • RSV患者慢性呼吸疾病比例更高(52% vs 39%,p=0.012),慢性心脏病比例更高(52% vs 41%,p=0.039)。
  • RSV患者住院时间更长(中位8天 vs 6天,p<0.001),抗流感治疗使用更少(20% vs 66%,p<0.001)。
  • 院内复合结局RSV患者更差(aPR 1.5,95%CI 1.1-2.1),出院后复合结局无差异(aPR 1.1,95%CI 0.8-1.6)。

关键数值与推荐

  • 院内复合结局包括至少发生一种并发症、住院≥7天、入住ICU、使用机械通气及院内死亡。
  • 出院后结局包括30天和90天全因死亡率及90天再入院率。

临床怎么用

  • 对因流感样疾病住院的成人,尤其高龄及有慢性呼吸或心脏病者,应考虑RSV检测。
  • RSV住院患者院内并发症风险较高,需加强住院期间监测与支持治疗。
  • RSV患者出院后中期结局与流感相似,出院后随访可参照流感管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to describe the clinical characteristics and in-hospital and post-discharge outcomes of respiratory syncytial virus (RSV) infection among adults hospitalised with influenza-like illness (ILI) and compared against patients admitted for influenza. METHODS: Adults hospitalised with ILI were prospectively included from five French university hospitals over two consecutive winter seasons (2017/2018 and 2018/2019). RSV and influenza virus were detected by multiplex reverse transcription PCR on nasopharyngeal swabs. RSV-positive patients were compared to RSV-negative and influenza-positive hospitalised patients. Poisson regression models were used to estimate the adjusted prevalence ratio (aPR) associated with in-hospital and post-discharge outcomes between RSV and influenza infections. The in-hospital outcome was a composite of the occurrence of at least one complication, length of stay ≥7 days, intensive care unit admission, use of mechanical ventilation and in-hospital death. Post-discharge outcome included 30- and 90-day all-cause mortality and 90-day readmission rates. RESULTS: Overall, 1428 hospitalised adults with ILI were included. RSV was detected in 8% (114 of 1428) and influenza virus in 31% (437 of 1428). Patients hospitalised with RSV were older than those with influenza (mean age 73.0 versus 68.8 years, p=0.015) with a higher frequency of chronic respiratory or cardiac disease (52% versus 39%, p=0.012, and 52% versus 41%, p=0.039, respectively) and longer hospitalisation duration (median stay 8 versus 6 days, p<0.001). Anti-influenza therapies were less prescribed among RSV patients than influenza patients (20% versus 66%, p<0.001). In-hospital composite outcome was poorer in RSV patients (aPR 1.5, 95% CI 1.1-2.1) than in those hospitalised with influenza. No difference was observed for the post-discharge composite outcome (aPR 1.1, 95% CI 0.8-1.6). CONCLUSION: RSV infection results in serious respiratory illness, with worse in-hospital outcomes than influenza and with similar midterm post-discharge outcomes.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Descamps A, Lenzi N, Galtier F, et al. In-hospital and midterm post-discharge complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study. Eur Respir J. 2022. PMID: 34446468. doi:10.1183/13993003.00651-2021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。